MCID: GLM025
MIFTS: 20

Glioma Susceptibility 2

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Glioma Susceptibility 2

MalaCards integrated aliases for Glioma Susceptibility 2:

Name: Glioma Susceptibility 2 54 29 13
Glioma 2 71
Glm2 71

Classifications:



External Ids:

OMIM 54 613028
MedGen 40 C2751642
MeSH 42 D005910

Summaries for Glioma Susceptibility 2

UniProtKB/Swiss-Prot : 71 Glioma 2: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

MalaCards based summary : Glioma Susceptibility 2, also known as glioma 2, is related to meningioma, familial. An important gene associated with Glioma Susceptibility 2 is PTEN (Phosphatase And Tensin Homolog). The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include brain.

Description from OMIM: 613028

Related Diseases for Glioma Susceptibility 2

Diseases in the Glioma Susceptibility 1 family:

Glioma Susceptibility 8 Glioma Susceptibility 9
Glioma Susceptibility 7 Glioma Susceptibility 5
Glioma Susceptibility 2 Glioma Susceptibility 4
Glioma Susceptibility 6

Diseases related to Glioma Susceptibility 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 meningioma, familial 10.9

Symptoms & Phenotypes for Glioma Susceptibility 2

Clinical features from OMIM:

613028

Drugs & Therapeutics for Glioma Susceptibility 2

Drugs for Glioma Susceptibility 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3
2 Antibodies, Monoclonal Phase 3
3 Antirheumatic Agents Phase 3
4 Immunoglobulins Phase 3
5
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
7 Alkylating Agents Phase 2
8
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
9 Protein Kinase Inhibitors Phase 2
10
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
11 Histone Deacetylase Inhibitors Phase 1
12
Bevacizumab Approved, Investigational 216974-75-3
13 Angiogenesis Inhibitors
14 Angiogenesis Modulating Agents

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Completed NCT00975130 Phase 3
2 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Recruiting NCT02689336 Phase 2 Temozolomide
3 High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma Terminated NCT01378481 Phase 1 Vorinostat
4 A Family Study of Adults With Glioma Completed NCT00339352
5 Gliogene: Brain Tumor Linkage Study Active, not recruiting NCT00418899
6 A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma Active, not recruiting NCT01939574

Search NIH Clinical Center for Glioma Susceptibility 2

Genetic Tests for Glioma Susceptibility 2

Genetic tests related to Glioma Susceptibility 2:

id Genetic test Affiliating Genes
1 Glioma Susceptibility 2 29

Anatomical Context for Glioma Susceptibility 2

MalaCards organs/tissues related to Glioma Susceptibility 2:

39
Brain

Publications for Glioma Susceptibility 2

Variations for Glioma Susceptibility 2

UniProtKB/Swiss-Prot genetic disease variations for Glioma Susceptibility 2:

71
id Symbol AA change Variation ID SNP ID
1 PTEN p.Arg234Gln VAR_018106 rs121909235

ClinVar genetic disease variations for Glioma Susceptibility 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.701G> A (p.Arg234Gln) single nucleotide variant Pathogenic,risk factor rs121909235 GRCh37 Chromosome 10, 89717676: 89717676

Expression for Glioma Susceptibility 2

Search GEO for disease gene expression data for Glioma Susceptibility 2.

Pathways for Glioma Susceptibility 2

GO Terms for Glioma Susceptibility 2

Sources for Glioma Susceptibility 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....